Content area
Full text
UPDATA
TAP Pharmaceutical Products has agreed to pay the government a record $875 million to settle extensive civil and criminal charges of illegally marketing and manipulating the costs of Lupron, a prostate cancer drug, under the Medicare and Medicaid programs, the Department of Justice (DOJ) announced October 3, 2001. The amount consists of $290 million in criminal fines and $585 million in civil penalties. The settlement amount surpasses the $840 million deal Nashville, Tennessee-based HCA, Inc., struck with the government last December. TAP also will enter into a seven-year corporate integrity agreement with the HHS Office of Inspector General. TAP is a joint venture between Takeda Chemical Industries, Osaka, Japan, and Abbott Laboratories,...